NASDAQ:LPDX

(LPDX) (LPDX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
LPDX stock logo

About (LPDX) Stock (NASDAQ:LPDX)

LipoScience, Inc. is a vitro diagnostic company. The Company’s diagnostic test, the nuclear magnetic resonance (NMR) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company’s Vantera system is the Company's automated clinical analyzer. As of January 25, 2013, over eight million NMR LipoProfile tests were ordered. The Vantera system is its automated clinical analyzer. In August 2012, the Company received Food and Drug Administration (FDA) clearance to market the Vantera system commercially to laboratories.

LPDX Stock News Headlines

The 2024 Gold Rush: Unleashing Market Potential
Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.
LPDX Historical Data
The 2024 Gold Rush: Unleashing Market Potential
Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.
See More Headlines
Receive LPDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (LPDX) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2014
Today
5/07/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LPDX
CUSIP
53630M10
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

LPDX Stock Analysis - Frequently Asked Questions

How were (LPDX)'s earnings last quarter?

(LPDX) (NASDAQ:LPDX) announced its earnings results on Wednesday, November, 12th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02. The biotechnology company had revenue of $8.56 million for the quarter, compared to analysts' expectations of $8.80 million. During the same quarter in the prior year, the firm posted ($0.31) earnings per share.

What other stocks do shareholders of (LPDX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (LPDX) investors own include Altaba (AABA), Global Sources Ltd. Bermuda (GSOL), Alcoa (AA), Agios Pharmaceuticals (AGIO), AerCap (AER), AEGR (AEGR), Aegon (AEG) and Acorda Therapeutics (ACOR).

This page (NASDAQ:LPDX) was last updated on 5/7/2024 by MarketBeat.com Staff

From Our Partners